Diabetic Med: 1型糖尿病患者从儿童转诊到成人对护理课程的服务和幸福感满意度

2018-11-01 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于一项纵向的观察性研究,评估 1型糖尿病患者从儿童转诊到成人对护理课程的服务和幸福感满意度。研究人员假设参与者的幸福感和对服务的满意度与从儿童到成人医疗保健过渡期间满意的临床过程正相关。 研究人员对来自英格兰五个糖尿病科的大约150名患有1型糖尿病的年轻人被招募进行纵向转变研究。研究助理对每个年轻人在家中进行4次随访,每次随访间

近日,国际杂志 《Diabetic Med》上在线发表一项关于一项纵向的观察性研究,评估 1糖尿病患者从儿童转诊到成人对护理课程的服务和幸福感满意度。研究人员假设参与者的幸福感和对服务的满意度与从儿童到成人医疗保健过渡期间满意的临床过程正相关。

研究人员对来自英格兰五个糖尿病科的大约150名患有1糖尿病的年轻人被招募进行纵向转变研究。研究助理对每个年轻人在家中进行4次随访,每次随访间隔1年,并获得了对服务(Mind the Gap; MTG)和幸福感(Warwick-Edinburgh Mental Well-being Scale; WEMWBS)的满意度。HbA 1c,酮症酸中毒,临床和视网膜筛查率的变化用于评估临床病程。通过4次的随访, 150名年轻人中有10872%)名有足够的数据进行分析。

研究显示,入组时的平均年龄为16岁。通过4年访问,81.5%的人离开了儿科医疗保健服务。中位数HbA 1c从基线时的69 mmol / mol8.5%)显著增加(P = 0.01)至第4次时的75 mmol / mol9.0%).研究期间,WEMWBS评分与基线时的一般人群相当且稳定。MTG得分也稳定。通过4次随访,大约32个人 “满意”和76个“次优”。临床病程组的平均WEMWBSMTG评分无显著差异(分别为P = 0.96,0.52 ; 临床病程组之间的转诊状况也没有显著差异。

研究显示,糖尿病年轻人的幸福感和对过渡服务的满意度与他们的临床病程并不是密切相关。调查创新性心理教育干预是否可以改善临床病程仍是研究的重点。

原始出处:

S. GrayT. CheethamH. McConet al. A longitudinal, observational study examining the relationships of patient satisfaction with services and mental wellbeing to their clinical course in young people with Type 1 diabetes mellitus during transition from child to adult health services

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-12-06 kalseyzl
  6. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 misszhang

    谢谢MedSci提供最新的资讯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1638837, encodeId=f3da163883e97, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 13 23:44:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760877, encodeId=d53a1e608774c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 21 13:44:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970661, encodeId=f91219e0661fa, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 21 15:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968270, encodeId=9b2519682e01f, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 14 15:44:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648611, encodeId=ab4e16486114a, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Thu Dec 06 00:44:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474638, encodeId=4ba014e463871, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478678, encodeId=5a3c14e8678a5, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609278, encodeId=eb5816092e84f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:44:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042006, encodeId=85871042006af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351187, encodeId=962c35118e90, content=非常棒,学习的榜样!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/01/f612f13e1d032bfba1058f1134beddf9.jpg, createdBy=40082474711, createdName=NSAIDS, createdTime=Thu Nov 01 16:33:05 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 NSAIDS

    非常棒,学习的榜样!

    0

相关资讯

Diabetic Med:客户和医疗保健专业人员的视角看1型糖尿病患者饮食失调

近日,国际杂志 《Diabetic Med》上在线发表一项关于1型糖尿病患者饮食失调的研究。探讨1型糖尿病患者和饮食失调患者以及医疗保健专业人员对其进行治疗的经验,了解双方的经验,从而为未来医疗服务的发展提供依据。 研究人员从饮食失调糖尿病患者协会(英国国家慈善机构)和专业网络招募参与者。9名部分/完全康复的1型糖尿病饮食障碍患者和8名医疗保健专业人员参加了由医学培训研究人员进行的半结构式访

Fiasp可有效控制1型糖尿病患者的血糖水平

在第44届国际儿科和青少年糖尿病学会年会上发布的最新数据显示,与传统门冬胰岛素相比,接受Fiasp(门冬胰岛素的超快速作用配方)的研究人群的总体血糖水平(HbA1c)降低幅度更大。

Diabetic Med:根据糖尿病诊断年龄,非洲裔美国人和美国白人1型糖尿病患者的成年后期死亡率

近日,国际杂志 《Diabetic Med》上在线发表一项关于根据糖尿病诊断年龄,非洲裔美国人和美国白人1型糖尿病患者的成年后期死亡率的研究。研究为估计社会经济地位较低非洲裔美国人和美国白人的总体和原因特定死亡率,并同时检查是否因糖尿病发病年龄不同而有任何过度风险。 研究人员使用南部社区队列研究,对一组年龄在40-79岁(平均50岁)的大多数低收入参与者进行了死亡率随访,其中包括在30岁之前

EASD 2014:我国1型糖尿病患者自身抗体阳性率调查结果公布

中山大学附属第三医院翁建平教授等在EASD 2014年会上公布了我国1型糖尿病患者自身抗体阳性率调查结果:我国成人1型糖尿病患者的自身抗体阳性率低于1型糖尿病高发国家。抗体阳性患者的临床进展更为迅速,与糖尿病自身抗体导致β细胞功能下降更快有关。(摘要号287) 研究数据来自于广东省1型糖尿病转化医学研究,本次分析共纳入1070例1型糖尿病患者,患者平均年龄为31.7岁,平均糖尿病病程为4

Lancet Diabetes Endo:达格列净能否改善1型糖尿病患者的血糖控制

2017年发表于《Lancet Diabetes Endocrinol》上的一项多中心、双盲、3期、随机对照试验,考察了达格列净在血糖未充分控制的1型糖尿病患者中的疗效和安全性(DEPICT-1)。

Diabetic Med:关于1型糖尿病患者饮食失调,患者和医疗保健专业人员的意见如何?

近日,国际杂志 《Diabetic Med》上在线发表一项关于1型糖尿病患者饮食失调,患者和医疗保健专业人员的意见的研究。探讨1型糖尿病患者和饮食失调患者以及医疗保健专业人员对其进行治疗的经验,通过了解双方的经验为未来医疗服务的发展提供依据。 研究人员从饮食失调糖尿病患者协会(英国国家慈善机构)和专业网络招募参与者。9名部分/完全康复的1型糖尿病饮食障碍患者和8名医疗保健专业人员参加了由医学